首页> 外文期刊>Aging cell. >Upregulation of PGC-1α expression by Alzheimer's disease-associated pathway: presenilin 1/amyloid precursor protein (APP)/intracellular domain of APP.
【24h】

Upregulation of PGC-1α expression by Alzheimer's disease-associated pathway: presenilin 1/amyloid precursor protein (APP)/intracellular domain of APP.

机译:阿尔茨海默病相关途径的PGC-1α表达的上调:Presenilin 1 /淀粉样蛋白前体蛋白(APP)/ APP的细胞内域。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Cleavage of amyloid precursor protein (APP) by β- and γ-secretase generates amyloid-β (Aβ) and APP intracellular domain (AICD) peptides. Presenilin (PS) 1 or 2 is the catalytic component of the γ-secretase complex. Mitochondrial dysfunction is an established phenomenon in Alzheimer's disease (AD), but the causes and role of PS1, APP, and APP's cleavage products in this process are largely unknown. We studied the effect of these AD-associated molecules on mitochondrial features. Using cells deficient in PSs expression, expressing human wild-type PS1, or PS1 familial AD (FAD) mutants, we found that PS1 affects mitochondrial energy metabolism (ATP levels and oxygen consumption) and expression of mitochondrial proteins. These effects were associated with enhanced expression of the mitochondrial master transcriptional coactivator PGC-1α and its target genes. Importantly, PS1-FAD mutations decreased PS1's ability to enhance PGC-1α mRNA levels. Analyzing the effect of APP and its γ-secretase-derived cleavage products Aβ and AICD on PGC-1α expression showed that APP and AICD increase PGC-1α expression. Accordingly, PGC-1α mRNA levels in cells deficient in APP/APLP2 or expressing APP lacking its last 15 amino acids were lower than in control cells, and treatment with AICD, but not with Aβ, enhanced PGC-1α mRNA levels in these and PSs-deficient cells. In addition, knockdown of the AICD-binding partner Fe65 reduced PGC-1α mRNA levels. Importantly, APP/AICD increases PGC-1α expression also in the mice brain. Our results therefore suggest that APP processing regulates mitochondrial function and that impairments in the newly discovered PS1/APP/AICD/PGC-1α pathway may lead to mitochondrial dysfunction and neurodegeneration.
机译:β-和γ-分泌酶用淀粉样蛋白前体蛋白(APP)的切割产生淀粉样蛋白-β(Aβ)和APP细胞内结构域(AICD)肽。 Presenilin(PS)1或2是γ-分泌酶复合物的催化组分。线粒体功能障碍是阿尔茨海默病(AD)的既定现象,但PS1,APP和APP在该过程中的发酵产品的原因和作用在很大程度上是未知数。我们研究了这些AD相关分子对线粒体特征的影响。使用缺乏PSS表达的细胞,表达人类野生型PS1或PS1家族性AD(FAD)突变体,我们发现PS1影响线粒体能量代谢(ATP水平和氧气消耗)和线粒体蛋白的表达。这些效应与线粒体母系转录共转录PGC-1α的增强表达有关,及其靶基因。重要的是,PS1-FAD突变降低了PS1增强PGC-1αmRNA水平的能力。分析应用的效果及其γ分泌酶衍生的切割产物Aβ和AICD对PGC-1α的表达显示,APP和AICD增加了PGC-1α表达。因此,在APP / APLP2或表达缺乏其后15个氨基酸的缺乏的细胞中的PGC-1αmRNA水平低于对照细胞,并用AICD处理,但不具有Aβ,增强这些和PSS的PGC-1αmRNA水平 - 细胞。此外,AIDD结合伴侣Fe65的敲低减少了PGC-1αmRNA水平。重要的是,APP / AICD也增加了小鼠脑中的PGC-1α表达。因此,我们的结果表明,应用处理调节线粒体功能,并且新发现的PS1 / APP / AICD / PGC-1α途径的损伤可能导致线粒体功能障碍和神经变性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号